Effects of rapamycin on DC-SIGN expression and biological functions in DC.

Rapamycin, a macrolide antibiotic, has potent immunosuppressive properties as an antirejection therapy in organ transplantation. Studies show that dendritic cells (DC) are important targets for rapamycin, which can inhibit DC maturation and DC-induced allogeneic T cell proliferation. In this study, we investigated the effects of rapamycin on the expressions of DC-SIGN and transcription factor PU.1 and the function of DC. Treatment with rapamycin significantly reduced the expression of DC-SIGN in a dose-dependent manner associated with suppression of PU.1 gene expression and the ability of DC to migrate and stimulate T cell proliferation. The expression of DC-SIGN was significantly suppressed using PU.1 siRNA. Intriguingly, rapamycin treatment largely decreased the expressions of PU.1 and DC-SIGN in THP-1 cells. In addition, treatment with rapamycin down-regulated the promoter activity of DC-SIGN. In conclusion, rapamycin inhibits DC-SIGN expression and suppresses the ability of DC to migrate and stimulate T cell proliferation through the PU.1 gene transcription pathway.

[1]  M. Joyce,et al.  DC-SIGN, C1q, and gC1qR form a trimolecular receptor complex on the surface of monocyte-derived immature dendritic cells. , 2012, Blood.

[2]  J. Li,et al.  Multiple Signaling Pathways Are Involved in the Interleukine-4 Regulated Expression of DC-SIGN in THP-1 Cell Line , 2012, Journal of biomedicine & biotechnology.

[3]  T. Huizinga,et al.  Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway: Commentary , 2011 .

[4]  Haishan Li,et al.  Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro , 2011, Cancer Immunology, Immunotherapy.

[5]  B. Pulendran,et al.  A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation , 2010, The Journal of Immunology.

[6]  J. Zhang,et al.  Rapamycin inhibits activator protein-1 but not nuclear factor-kappaB activity of mature bone marrow-derived dendritic cells. , 2010, Transplantation proceedings.

[7]  U. Švajger,et al.  C-type lectin DC-SIGN: An adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity , 2010, Cellular Signalling.

[8]  S. Gringhuis,et al.  Pathogen recognition by DC-SIGN shapes adaptive immunity. , 2009, Future microbiology.

[9]  J. Garcia-Vallejo,et al.  Endogenous ligands for C‐type lectin receptors: the true regulators of immune homeostasis , 2009, Immunological reviews.

[10]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[11]  R. Martinez-Nunez,et al.  MicroRNA-155 Modulates the Pathogen Binding Ability of Dendritic Cells (DCs) by Down-regulation of DC-specific Intercellular Adhesion Molecule-3 Grabbing Non-integrin (DC-SIGN)* , 2009, The Journal of Biological Chemistry.

[12]  F. Schmitz,et al.  Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells , 2008, European journal of immunology.

[13]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[14]  S. Carotta,et al.  Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment. , 2006, Genes & development.

[15]  A. Puig-Kröger,et al.  PU.1 Regulates the Tissue-specific Expression of Dendritic Cell-specific Intercellular Adhesion Molecule (ICAM)-3-grabbing Nonintegrin* , 2005, Journal of Biological Chemistry.

[16]  G. Meijer,et al.  Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. , 2005, Cancer research.

[17]  A. Rice,et al.  Isolation and characterization of the human DC-SIGN and DC-SIGNR promoters. , 2003, Gene.

[18]  A. Thomson,et al.  Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. , 2003, Blood.

[19]  P. Allavena,et al.  Rapamycin impairs antigen uptake of human dendritic cells1 , 2003, Transplantation.

[20]  G. Pendl,et al.  Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. , 2002, Blood.

[21]  A. Macdonald.  A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS , 2001, Transplantation.

[22]  Carl G. Figdor,et al.  DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking , 2000, Nature Immunology.

[23]  L. Schwarzfischer,et al.  PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene* , 2000, The Journal of Biological Chemistry.

[24]  R. Steinman.  DC-SIGN A Guide to Some Mysteries of Dendritic Cells , 2000, Cell.

[25]  C. Figdor,et al.  Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses , 2000, Cell.

[26]  V. Shepherd,et al.  PU.1 and USF Are Required for Macrophage-specific Mannose Receptor Promoter Activity* , 1999, The Journal of Biological Chemistry.

[27]  D. Raveh,et al.  Murine macrophage mannose receptor promoter is regulated by the transcription factors PU.1 and SP1. , 1997, Blood.

[28]  H. Randeva,et al.  High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. , 2011, Immunobiology.

[29]  Xiao Li,et al.  Effects of DC-SIGN expression on renal tubulointerstitial fibrosis in nephritis. , 2009, Frontiers in bioscience.

[30]  D. Agrawal,et al.  Transcription factors in the control of dendritic cell life cycle , 2007, Immunologic research.

[31]  N. Sigal,et al.  Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. , 1992, Annual review of immunology.